JP2018141025A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018141025A5 JP2018141025A5 JP2018118937A JP2018118937A JP2018141025A5 JP 2018141025 A5 JP2018141025 A5 JP 2018141025A5 JP 2018118937 A JP2018118937 A JP 2018118937A JP 2018118937 A JP2018118937 A JP 2018118937A JP 2018141025 A5 JP2018141025 A5 JP 2018141025A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- composition according
- dose
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022144425A JP7581292B2 (ja) | 2017-01-31 | 2022-09-12 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2024190237A JP2025016617A (ja) | 2017-01-31 | 2024-10-30 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201700775YA SG10201700775YA (en) | 2017-01-31 | 2017-01-31 | A Pharmaceutical Composition For Use In The Treatment Or Prevention Of A C5-Related Disease And A Method For Treating Or Preventing A C5-Related Disease |
| SG10201700775Y | 2017-01-31 | ||
| SG10201705954VA SG10201705954VA (en) | 2017-07-20 | 2017-07-20 | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease |
| SG10201705954V | 2017-07-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018014743A Division JP6383122B2 (ja) | 2017-01-31 | 2018-01-31 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022144425A Division JP7581292B2 (ja) | 2017-01-31 | 2022-09-12 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018141025A JP2018141025A (ja) | 2018-09-13 |
| JP2018141025A5 true JP2018141025A5 (https=) | 2021-03-11 |
| JP7141865B2 JP7141865B2 (ja) | 2022-09-26 |
Family
ID=61617058
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018014743A Active JP6383122B2 (ja) | 2017-01-31 | 2018-01-31 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2018118937A Active JP7141865B2 (ja) | 2017-01-31 | 2018-06-22 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2022144425A Active JP7581292B2 (ja) | 2017-01-31 | 2022-09-12 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2024190237A Pending JP2025016617A (ja) | 2017-01-31 | 2024-10-30 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018014743A Active JP6383122B2 (ja) | 2017-01-31 | 2018-01-31 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022144425A Active JP7581292B2 (ja) | 2017-01-31 | 2022-09-12 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
| JP2024190237A Pending JP2025016617A (ja) | 2017-01-31 | 2024-10-30 | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20190367599A1 (https=) |
| EP (2) | EP4223774A3 (https=) |
| JP (4) | JP6383122B2 (https=) |
| KR (4) | KR101949891B1 (https=) |
| CN (1) | CN110167961A (https=) |
| AU (2) | AU2018215039B2 (https=) |
| BR (1) | BR112019015426A2 (https=) |
| CA (1) | CA3051389A1 (https=) |
| CR (2) | CR20190403A (https=) |
| ES (1) | ES2947735T3 (https=) |
| IL (2) | IL307593A (https=) |
| MX (2) | MX2019007749A (https=) |
| MY (1) | MY201148A (https=) |
| PH (1) | PH12019501706A1 (https=) |
| PL (1) | PL3577135T3 (https=) |
| SG (2) | SG11201801401UA (https=) |
| TW (3) | TWI658834B (https=) |
| UA (1) | UA129282C2 (https=) |
| WO (1) | WO2018143266A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2892925T3 (es) | 2006-03-31 | 2022-02-07 | Chugai Pharmaceutical Co Ltd | Métodos para controlar la farmacocinética en sangre de anticuerpos |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| TWI812066B (zh) | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| KR101860280B1 (ko) | 2014-12-19 | 2018-05-21 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| CN107207607B (zh) | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| CN114773470A (zh) | 2015-02-05 | 2022-07-22 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用 |
| US11359009B2 (en) | 2015-12-25 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| JP2019517473A (ja) | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| ES2984352T3 (es) | 2016-06-14 | 2024-10-29 | Regeneron Pharma | Anticuerpos anti-C5 y usos de los mismos |
| TWI693940B (zh) | 2016-08-05 | 2020-05-21 | 日商中外製藥股份有限公司 | Ｉｌ-８相關疾病之治療用或預防用組成物 |
| CA3080187A1 (en) * | 2017-10-26 | 2019-05-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus) |
| MA51147A (fr) | 2017-12-13 | 2021-03-24 | Regeneron Pharma | Associations d'anticorps anti-c5 et utilisations associées |
| JP7577542B2 (ja) | 2018-06-04 | 2024-11-05 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 小児患者における非典型溶血性尿毒症症候群（ａＨＵＳ）の治療のための抗Ｃ５抗体の用量および投与 |
| CN112996561A (zh) * | 2018-10-30 | 2021-06-18 | 亚力兄制药公司 | 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用 |
| CN115068604A (zh) * | 2019-07-31 | 2022-09-20 | 豪夫迈·罗氏有限公司 | 通过使用抗c5抗体可伐利单抗来治疗或预防c5相关疾病的剂量和施用方案 |
| WO2021019033A1 (en) * | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab |
| JP7798763B2 (ja) * | 2019-10-25 | 2026-01-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃ５関連疾患の治療または予防のための投与レジメン |
| CA3196434A1 (en) * | 2020-10-23 | 2022-04-28 | Krista K. JOHNSON | Methods of treating patients having complement disorders using anti-c5 antibodies |
| JP2024060738A (ja) | 2022-10-20 | 2024-05-07 | セイコーエプソン株式会社 | 気体分離膜 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| AU2001296594A1 (en) | 2000-10-10 | 2002-04-22 | Tanox, Inc. | Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection |
| BRPI0211953B8 (pt) | 2001-08-17 | 2021-05-25 | Genentech Inc | anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP3263596A1 (en) | 2002-12-16 | 2018-01-03 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
| US20070116710A1 (en) | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
| KR100891620B1 (ko) | 2004-04-13 | 2009-04-02 | 에프. 호프만-라 로슈 아게 | 항-ｐ-셀렉틴 항체 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| PL3167888T3 (pl) | 2006-03-15 | 2024-08-26 | Alexion Pharmaceuticals, Inc. | Leczenie pacjentów z napadową nocną hemoglobinurią za pomocą inhibitora dopełniacza |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| LT2894165T (lt) | 2008-11-10 | 2023-03-10 | Alexion Pharmaceuticals, Inc. | Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui |
| SG183867A1 (en) | 2010-03-11 | 2012-10-30 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
| TWI667346B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
| CA3216595A1 (en) * | 2013-03-14 | 2014-10-02 | Kevin Fitzgerald | Complement component c5 irna compositions and methods of use thereof |
| ES2768648T3 (es) * | 2013-03-29 | 2020-06-23 | Alexion Pharma Inc | Composiciones y métodos para aumentar la semivida en suero de un agente terapéutico dirigido a C5 del complemento |
| NZ631007A (en) * | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| CN107207607B (zh) | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| EP3313437A1 (en) * | 2015-06-26 | 2018-05-02 | Alexion Pharmaceuticals, Inc. | A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant |
| EP3402816A1 (en) | 2016-01-11 | 2018-11-21 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| EP3408291A1 (en) | 2016-01-25 | 2018-12-05 | Shire Human Genetic Therapies, Inc. | Anti-c5 antibodies with enhanced ph switch |
-
2018
- 2018-01-31 IL IL307593A patent/IL307593A/en unknown
- 2018-01-31 TW TW107103450A patent/TWI658834B/zh active
- 2018-01-31 MY MYPI2019004320A patent/MY201148A/en unknown
- 2018-01-31 KR KR1020187009861A patent/KR101949891B1/ko active Active
- 2018-01-31 SG SG11201801401UA patent/SG11201801401UA/en unknown
- 2018-01-31 CA CA3051389A patent/CA3051389A1/en active Pending
- 2018-01-31 KR KR1020227005327A patent/KR102514175B1/ko active Active
- 2018-01-31 MX MX2019007749A patent/MX2019007749A/es unknown
- 2018-01-31 EP EP23165354.4A patent/EP4223774A3/en active Pending
- 2018-01-31 TW TW112148241A patent/TW202412841A/zh unknown
- 2018-01-31 IL IL268327A patent/IL268327B2/en unknown
- 2018-01-31 EP EP18710159.7A patent/EP3577135B1/en active Active
- 2018-01-31 UA UAA201909498A patent/UA129282C2/uk unknown
- 2018-01-31 AU AU2018215039A patent/AU2018215039B2/en active Active
- 2018-01-31 CR CR20190403A patent/CR20190403A/es unknown
- 2018-01-31 WO PCT/JP2018/003193 patent/WO2018143266A1/en not_active Ceased
- 2018-01-31 SG SG10201908697X patent/SG10201908697XA/en unknown
- 2018-01-31 BR BR112019015426-4A patent/BR112019015426A2/pt unknown
- 2018-01-31 PL PL18710159.7T patent/PL3577135T3/pl unknown
- 2018-01-31 TW TW108110617A patent/TWI828672B/zh active
- 2018-01-31 US US16/480,047 patent/US20190367599A1/en not_active Abandoned
- 2018-01-31 KR KR1020237009640A patent/KR20230043247A/ko not_active Ceased
- 2018-01-31 JP JP2018014743A patent/JP6383122B2/ja active Active
- 2018-01-31 ES ES18710159T patent/ES2947735T3/es active Active
- 2018-01-31 CN CN201880005975.XA patent/CN110167961A/zh active Pending
- 2018-01-31 CR CR20220563A patent/CR20220563A/es unknown
- 2018-01-31 KR KR1020197004219A patent/KR102365871B1/ko active Active
- 2018-06-22 JP JP2018118937A patent/JP7141865B2/ja active Active
-
2019
- 2019-06-26 MX MX2022012931A patent/MX2022012931A/es unknown
- 2019-07-24 PH PH12019501706A patent/PH12019501706A1/en unknown
-
2020
- 2020-07-14 US US16/928,129 patent/US20200407432A1/en not_active Abandoned
-
2022
- 2022-09-12 JP JP2022144425A patent/JP7581292B2/ja active Active
-
2023
- 2023-03-10 US US18/181,641 patent/US20230250162A1/en active Pending
-
2024
- 2024-08-23 AU AU2024216280A patent/AU2024216280A1/en not_active Abandoned
- 2024-10-30 JP JP2024190237A patent/JP2025016617A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018141025A5 (https=) | ||
| KR102365871B1 (ko) | C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법 | |
| US9636334B2 (en) | Combination of lenalidomide and polypeptide construct, and uses thereof | |
| JP6672516B2 (ja) | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 | |
| ES2783448T3 (es) | Métodos de tratamiento del lupus eritematoso sistémico utilizando un anticuerpo de dominio dirigido contra CD28 | |
| JP2005516917A (ja) | 細胞外アデノシン阻害剤およびアデノシン受容体阻害剤を用いて免疫応答および炎症を増強するための方法 | |
| KR102321372B1 (ko) | 인터류킨-6에 대한 항체 및 그의 용도 | |
| JP2020019769A5 (https=) | ||
| US11014973B2 (en) | Fusion proteins for treating cancer and related methods | |
| US9365652B2 (en) | Use of IL-20 antagonists for treating liver diseases | |
| KR20160079918A (ko) | Ｖｅｇｆ 억제제 및 이리노테칸을 함유하는 항종양 조합물 | |
| WO2021213523A1 (zh) | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 | |
| JP2022104920A5 (https=) | ||
| JP2020150947A (ja) | 抗ポドプラニン抗体 | |
| US9982043B2 (en) | Use of IL-20 antagonists for treating pancreatic cancer | |
| US9376490B2 (en) | Treatment of inflammatory pain using IL-20 antagonists | |
| JP2022101535A5 (https=) | ||
| Moss | Mechanism of action and pharmacokinetics of biologics | |
| US9751949B2 (en) | Method of inhibiting adipogenesis with an IL-20 antibody | |
| US12409208B2 (en) | Treating tissue fibrosis with interleukin 24 | |
| CN118767126A (zh) | 抗cd47抗体和阿扎胞苷联合治疗血液肿瘤 | |
| RU2022103727A (ru) | Дозировка и схема введения для лечения или предупреждения связанных с с5 заболеваний посредством применения антитела против с5 кровалимаба | |
| WO2025113598A1 (zh) | 稳定的混合抗体的药物组合物 | |
| RU2022103731A (ru) | Дозировка и схема введения для лечения или предупреждения связанных с с5 заболеваний посредством применения антитела против с5 кровалимаба | |
| EP3280732A1 (en) | Antibodies binding to canine vascular endothelial growth factor and uses thereof in treating canine angiogenesis-related diseases |